Pipeline Programs↗
Active Trials↗
Companies Involved↗
Bupivacaine is an emerging landscape with 27 programs across 10 companies. 5 programs are in Phase 3.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Analysis
96%
Small molecule
24 of 25 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 93% of 27 pipeline programs.
Analysis
245
clinical trials
Clinical Trials
245 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)